Pancreatic Cancer

P2, N=80, Recruiting, Corcept Therapeutics | N=60 --> 80

P=N/A, N=20, Not yet recruiting, Case Comprehensive Cancer Center

Down-regulated expression of CDH1 has potential as a predictive marker of poor prognosis in PC patients. However, further high-quality and large-scale clinical studies are required to validate our findings.

Importantly, findings from the clinical cohort confirmed that ITGA3 expression was positively correlated with CD206 and PD-L1, and negatively correlated with CD8 and CD19, supporting its role in shaping an immunosuppressive microenvironment. ITGA3 is a promising immune-related biomarker for predicting prognosis and therapeutic response in PDAC and may provide a potential target for personalized treatment strategies.

The TMEp phase integrated stereotactic body radiotherapy (SBRT), low-dose etoposide, and anlotinib, followed by CI with the programmed death 1 (PD-1)/cytotoxic T lymphocyte antigen 4 (CTLA-4) bispecific antibody cadonilimab and concurrent probiotic supplementation...The TMEp-CI-M platform may enhance the efficacy of immunotherapy in ES-SCLC, enabling durable responses even in patients with brainstem metastases. Although this platform has demonstrated promise across multiple tumor types, further prospective and mechanistic studies are warranted to confirm its clinical utility.

CFSs from L. casei and L. rhamnosus showed anticancer effects on PANC-1 cells, inducing apoptosis, S-phase arrest, and a favorable shift in apoptosis-related gene expression. These findings highlight their potential as promising adjuvant candidates for pancreatic cancer therapy.

Codon optimization and in silico cloning into an Escherichia coli expression system were also successfully performed. Based on our findings, the proposed vaccine shows promise for targeting PC, warranting further experimental validation in animal models.

Accumulating evidence highlights the potential role of FXYD3 as an emerging biomarker with relevance to diagnosis, prognosis, and therapeutics. This review provides an overview of FXYD3's role in cancer biology from translational relevance to its potential as a diagnostic, prognostic, and therapeutic target.

Pg promotes oncogenic processes. CA modulates proliferation in a cell‑type‑ and concentration‑dependent manner, likely through Nrf2 activation.

At single-cell resolution, this study characterizes the LMIC population in PDAC and implicates a CAF-associated SEMA3A-NRP1 signaling axis within their spatial and functional microenvironmental niches. These findings provide a refined conceptual framework for the development of prospective targeted strategies aimed at disrupting early microenvironmental cross-talk associated with PDAC liver metastasis.

This alteration enhanced CD8+ T-cell recruitment and activation, ultimately sensitizing pancreatic cancer to immunotherapy. Collectively, our findings support ADAR1 inhibition combined with immunotherapy as a promising therapeutic strategy for pancreatic cancer.

BRCA-associated pancreatic ductal adenocarcinomas demonstrate recurrent morphologic patterns, including increased glandularity, stromal hyalinization, myxoid stromal change and architectural heterogeneity. These observations provide a framework for future comparative studies investigating morphologic correlates of homologous recombination deficiency in pancreatic cancer. Recognition of these patterns may support consideration of germline or somatic DNA-repair gene testing in appropriate clinical settings.